Roivant reported new mid-stage success for mosliciguat, an inhaled therapy for serious pulmonary hypertension. In a 16-week Phase 2 study, the company said the drug achieved a statistically significant 56% placebo-adjusted reduction in pulmonary vascular resistance, alongside multiple key secondary improvements. Roivant also highlighted gains in six-minute walk distance and reductions in NT-proBNP, metrics used to track cardiopulmonary function and heart failure risk. The update builds confidence in the program Roivant acquired, and it may strengthen the company’s ability to fund subsequent development steps. The readout arrives as investors continue to re-rate respiratory and cardiopulmonary assets with clear early signals, particularly inhaled or combination-ready candidates.